Searched for
MORAIYA
Buy Cadila Healthcare, target Rs 315: Nirmal Bang SecuritiesCadila Healthcare is a largecap company, operating in pharmaceuticals and health care sector.- CLSA downgrades Cadila Healthcare to 'sell'US FDA recently inspected Cadila's Moraiya facility and issued a Form 483 with 14 observations.
- Zydus Cadila shares rise 3.41% after USFDA clears Moraiya plantThe USFDA inspected Cadila’s Moraiya facility from August 31-September 7.
- Cadila receives audit closure reportThe Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations, the company said.
- Will bring our latest drug Lialda by August: Nitin Kumar Parekh, Director - Finance, CadilaCadila will bring out its latest drug, Lialda, in July or August, revealed Nitin Kumar Parekh, Director - Finance, Cadila.
- Cadila Healthcare surges 7% on receiving USFDA approval for levofloxacin injectionThe stock climbed 7.18 per cent to hit a high of Rs 504.8 on BSE.
- Zydus Cadila gets USFDA nod for levofloxacin injectionThe Gujarat group has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced fi...
- RBL Bank among top trading ideas for next week: Yogesh Mehta, Motilal Oswal SecuritiesMehta says Cadila Healthcare has been re-rated after the drugmaker received USFDA clearance for its Moraiya plant. The target price has bee...
- CLSA raises target price of Cadila Healthcare; should you buy?The global brokerage house said, “Moraiya outcome a big surprise but approvals may take time.” CLSA believes benefits of Moraiya's clearanc...
- Cadila Healthcare surges 20% as USFDA issues no observation for Moraiya facility“At the end of the inspection, no observation (483) is issued,” the company said in a brief filing to BSE.
- USFDA inspects Cadila Healthcare's Moraiya facility"USFDA inspected company's Moraiya facility from February 6, 2017 to February 15, 2017. At the end of the inspection no observation (483) i...
- Cadila gets EIR from USFDA for Changodar facilityLast month, Cadila Healthcare had received Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facilit...
- Outperform Cadila Healthcare Ltd., target Rs 405: Credit SuisseThe June quarter results are likely to remain weak given competition in HCQS, lower share in key drugs. Once Moraiya is cleared, Cadila sho...
- Overweight Cadila Healthcare Ltd., target Rs 399 : Morgan StanleyMorgan Stanley estimates that Cadila can generate up to $35 million upside and could generate over 90 per cent in PBT margins
- Cadila Healthcare gets EIR from USFDA for Moraiya facility"What is 'closed' is the initial review that resulted in the warning letter issuance," Cadila Healthcare said.
- Outperform on Cadila Healthcare with a target at Rs 400: MacquarieMultiples could be under pressure in the near-term on Moraiya remediation and future approvals,
- Cadila Healthcare extends losses; company clarifiesThe stock fell 2.97 per cent to hit a low of Rs 313.60 on BSE. This was the third day of consecutive fall for the stock.
- Cadila gets US FDA warning for violating standards at Moraiya and Ahmedabad plantsThe company said its Moraiya and Ahmedabad facilities have been cited in the letter, and it is working on responding to the FDA concerns re...
- Cadila Healthcare plunges 17% on USFDA warning letterShares of Cadila Healthcare plunged 17 per cent on Thursday after the pharmaceutical company received two warning letters Moraiya formulati...
- Brokers’ Call: Citi stays neutral on CadilaFY13 so far has been a challenging year with pressure on profitability due to increased costs despite registering strong revenue growth.
Load More
